p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy
- 1 May 2001
- Vol. 57 (5) , 852-859
- https://doi.org/10.1016/s0090-4295(01)00968-2
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- P53 MUTATIONS IN BLADDER TUMORS INACTIVATE THE TRANSACTIVATION OF THE P21 AND BAX GENES, AND HAVE A PREDICTIVE VALUE FOR THE CLINICAL OUTCOME AFTER BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, 1999
- Clinical Significance of mdm2 and p53 Expression in Bladder CancerOncology, 1999
- CORRELATION AND PROGNOSTIC SIGNIFICANCE OF p53, p21 WAF1/CIP1 AND Ki-67 EXPRESSION IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS TREATED WITH BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPYJournal of Urology, 1999
- Prognostic factors in muscle‐invasive bladder cancer treated with radiotherapy: an immunohistochemical studyBritish Journal of Urology, 1998
- Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial CarcinomasJapanese Journal of Cancer Research, 1998
- p53 and treatment of bladder cancerNature, 1997
- bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancerInternational Journal of Cancer, 1996
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Apoptosis in bladder cancer as related to standard prognostic factors and prognosisThe Journal of Pathology, 1994
- Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progressionBritish Journal of Urology, 1994